 |
27 Products |  |
14 Diseases | | 27 Products |
|
13 Trials |  |
837 News |  |
| «123456789» |
- || INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Enrollment open: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Jun 6, 2018
P1, N=32, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting
- ||||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
New P1/2 trial, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Apr 18, 2018
P1/2, N=85, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
New P2 trial: VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 (clinicaltrials.gov) - Apr 17, 2018
P2, N=24, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- ||| MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial initiation date, Metastases: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers (clinicaltrials.gov) - Apr 12, 2018
P2, N=77, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Recruiting Initiation date: Mar 2018 --> Jun 2018
- ||||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
New P1/2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Apr 8, 2018
P1/2, N=52, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Trial suspension: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Apr 5, 2018
P1, N=32, Suspended, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 2018 --> Jun 2018 Recruiting --> Suspended
- bizalimogene ralaplasmid (VGX-3100) / Inovio
Trial completion date, Combination therapy: Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) (clinicaltrials.gov) - Mar 26, 2018
P2, N=36, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Suspended Trial completion date: Aug 2020 --> Sep 2021
- | PENNVAX-GP (HIV DNA vaccine) / Inovio
Trial completion, Trial primary completion date: Evaluating the Safety and Immunogenicity of PENNVAX (clinicaltrials.gov) - Mar 13, 2018
P1, N=94, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Aug 2020 --> Sep 2021 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jun 2017
- || Enrollment closed, Combination therapy, Surgery: hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (clinicaltrials.gov) - Mar 13, 2018
P1, N=93, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jun 2017 Recruiting --> Active, not recruiting
- | MEDI0457 / AstraZeneca
Trial completion, Trial completion date: Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 7, 2018
P1/2, N=22, Completed, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Nov 2017
- MEDI0457 / AstraZeneca
Trial completion, Trial completion date, Trial primary completion date: A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer (clinicaltrials.gov) - Mar 1, 2018
P1/2, N=10, Completed, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Nov 2017 Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Sep 2017 | Trial primary completion date: Sep 2017 --> Sep 2017
- ||||| MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
New P2 trial, Metastases: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers (clinicaltrials.gov) - Feb 20, 2018
P2, N=77, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| INO-5150 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Trial completion, Trial primary completion date, Combination therapy: Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer (clinicaltrials.gov) - Dec 26, 2017
P1, N=62, Completed, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Sep 2017 | Trial primary completion date: Sep 2017 --> Sep 2017 Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Dec 2017
- || Enrollment change, Combination therapy, Surgery: hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (clinicaltrials.gov) - Nov 24, 2017
P1, N=90, Recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Dec 2017 N=54 --> 90
- || INO-1800 / Inovio, INO-9112 / Inovio
Enrollment closed, P1 data, Combination therapy: Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects (clinicaltrials.gov) - Sep 11, 2017
P1, N=90, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
N=54 --> 90 Recruiting --> Active, not recruiting
- | MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Metastases: Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Sep 5, 2017
P1b/2a, N=40, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | INO-8000 / Inovio
Trial completion: VGX-6150-01: Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (clinicaltrials.gov) - Aug 7, 2017
P1, N=18, Completed, Sponsor: GeneOne Life Science, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
Enrollment open, Combination therapy: Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) (clinicaltrials.gov) - Jul 21, 2017
P2, N=36, Recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||| bizalimogene ralaplasmid (VGX-3100) / Inovio
Enrollment open: REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (clinicaltrials.gov) - Jun 20, 2017
P3, N=198, Recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| bizalimogene ralaplasmid (VGX-3100) / Inovio
New P3 trial: REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (clinicaltrials.gov) - Jun 14, 2017
P3, N=198, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
New P2 trial, Combination therapy: Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) (clinicaltrials.gov) - Jun 7, 2017
P2, N=36, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Enrollment closed: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Apr 12, 2017
P1, N=240, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Enrollment open, Enrollment change, Trial primary completion date: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Mar 14, 2017
P1, N=240, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | N=200 --> 240 | Trial primary completion date: Dec 2017 --> May 2018
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Enrollment closed: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Nov 15, 2016
P1, N=200, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Recruiting | N=200 --> 240 | Trial primary completion date: Dec 2017 --> May 2018 Recruiting --> Active, not recruiting
- ||| New P1 trial, Combination therapy, Surgery: hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (clinicaltrials.gov) - Nov 8, 2016
P1, N=54, Recruiting, Sponsor: Inovio Pharmaceuticals
- PENNVAX-GP (HIV DNA vaccine) / Inovio
Enrollment closed: Evaluating the Safety and Immunogenicity of PENNVAX (clinicaltrials.gov) - Oct 18, 2016
P1, N=94, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial primary completion date: WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation (clinicaltrials.gov) - Oct 13, 2016
P2, N=184, Suspended, Sponsor: University Hospital Southampton NHS Foundation Trust.
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2014 --> Apr 2013
- || INO-1800 / Inovio, INO-9112 / Inovio
P1 data, Enrollment change, Trial primary completion date, Combination therapy: Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects (clinicaltrials.gov) - Sep 9, 2016
P1, N=90, Recruiting, Sponsor: Inovio Pharmaceuticals
Trial primary completion date: Apr 2014 --> Apr 2013 N=126 --> 90 | Trial primary completion date: Dec 2018 --> Aug 2018
- MEDI0457 / AstraZeneca
Enrollment closed, Enrollment change, Trial primary completion date: A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer (clinicaltrials.gov) - Aug 30, 2016
P1/2, N=10, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
N=126 --> 90 | Trial primary completion date: Dec 2018 --> Aug 2018 Recruiting --> Active, not recruiting | N=30 --> 10 | Trial primary completion date: Apr 2019 --> Sep 2017
- ||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Enrollment open, Enrollment change, Trial primary completion date: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Aug 24, 2016
P1, N=200, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting | N=30 --> 10 | Trial primary completion date: Apr 2019 --> Sep 2017 Active, not recruiting --> Recruiting | N=75 --> 200 | Trial primary completion date: Dec 2016 --> Dec 2017
- INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Enrollment open: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Aug 17, 2016
P1, N=32, Recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Recruiting | N=75 --> 200 | Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- || INO-4700 / GeneOne, Inovio
Enrollment closed: Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Jul 27, 2016
P1, N=75, Active, not recruiting, Sponsor: GeneOne Life Science, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || INO-5150 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Enrollment closed, Combination therapy: Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer (clinicaltrials.gov) - Jul 13, 2016
P1, N=60, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
New P1 trial: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Jul 5, 2016
P1, N=32, Recruiting, Sponsor: Mayo Clinic
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-1400 / Inovio
Trial primary completion date, Combination therapy, Surgery: Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers (clinicaltrials.gov) - Jun 16, 2016
P1, N=54, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- | MEDI0457 / AstraZeneca
Enrollment closed, Trial primary completion date: Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=22, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2016
- MEDI0457 / AstraZeneca
Enrollment change, Trial withdrawal, Combination therapy, Metastases: A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer (clinicaltrials.gov) - May 13, 2016
P2, N=0, Withdrawn, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2016 N=126 --> 0 | Not yet recruiting --> Withdrawn
- | INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
New P1 trial: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - May 13, 2016
P1, N=32, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- PENNVAX-GP (HIV DNA vaccine) / Inovio
Trial primary completion date: Evaluating the Safety and Immunogenicity of PENNVAX (clinicaltrials.gov) - Mar 9, 2016
P1, N=94, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=126 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Aug 2016 --> Nov 2017
- ||| INO-4700 / GeneOne, Inovio
Enrollment open: Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Feb 28, 2016
P1, N=75, Recruiting, Sponsor: GeneOne Life Science, Inc.
Trial primary completion date: Aug 2016 --> Nov 2017 Not yet recruiting --> Recruiting
- || INO-1800 / Inovio, INO-9112 / Inovio
P1 data, Trial primary completion date, Combination therapy: Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects (clinicaltrials.gov) - Feb 24, 2016
P1, N=126, Recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2017 --> Dec 2018
- |||| bizalimogene ralaplasmid (VGX-3100) / Inovio
Trial completion, Biopsy: A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 (clinicaltrials.gov) - Feb 24, 2016
P2, N=167, Completed, Sponsor: Inovio Pharmaceuticals
Trial primary completion date: Nov 2017 --> Dec 2018 Active, not recruiting --> Completed
- rocakinogene sifuplasmid (INO-9012) / Inovio, INO-3106 / Inovio
Trial primary completion date: Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies (clinicaltrials.gov) - Feb 23, 2016
P1, N=6, Recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Apr 2016 --> Jun 2018
- ||| INO-4700 / GeneOne, Inovio
New P1 trial: Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Feb 1, 2016
P1, N=75, Not yet recruiting, Sponsor: GeneOne Life Science, Inc.
- ||| MEDI0457 / AstraZeneca
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer (clinicaltrials.gov) - Jan 15, 2016
P2, N=126, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Apr 2016 --> Jun 2018 Initiation date: Dec 2015 --> May 2016 | Trial primary completion date: Dec 2018 --> May 2019
- | MEDI0457 / AstraZeneca
Enrollment change, Trial primary completion date: Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=25, Recruiting, Sponsor: Inovio Pharmaceuticals
Initiation date: Dec 2015 --> May 2016 | Trial primary completion date: Dec 2018 --> May 2019 N=20 --> 25 | Trial primary completion date: Jun 2017 --> Dec 2017
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Enrollment closed: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Oct 19, 2015
P1, N=75, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
N=20 --> 25 | Trial primary completion date: Jun 2017 --> Dec 2017 Recruiting --> Active, not recruiting
- PENNVAX-GP (HIV DNA vaccine) / Inovio
Enrollment open: Evaluating the Safety and Immunogenicity of PENNVAX (clinicaltrials.gov) - Sep 9, 2015
P1, N=94, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- PENNVAX-G / Inovio
Trial completion: Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults (clinicaltrials.gov) - Aug 27, 2015
P1, N=92, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | MEDI0457 / AstraZeneca
Enrollment change, Trial primary completion date: A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer (clinicaltrials.gov) - Aug 25, 2015
P1/2, N=30, Recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed N=20 --> 30 | Trial primary completion date: Apr 2016 --> Apr 2019